Current Opinion in the Treatment of Opportunistic Fungal Infections.
- Author:
Jin Hong YOO
1
;
Wan Shik SHIN
Author Information
1. Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
- Publication Type:Comparative Study ; Original Article
- Keywords:
Opportunistic fungal infections;
Treatment
- MeSH:
Amphotericin B;
Antifungal Agents;
Humans;
Immunocompromised Host;
Mortality
- From:Korean Journal of Medical Mycology
1997;2(1):9-16
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Opportunistic fungal infections are significant causes of mortality and morbidity especially among the immunocompromised hosts. There is now increasing array of drugs available for their treatment. Amphotericin B is the most established and widely used antifungal agent and lipid-complexed amphotericin B preparations are introduced recently. The imidazole and triazole drugs have specific roles to play on the management of these patients. However, antifungal therapy is still limited by the lack of effective agents, lack of early diagnostic techniques to identify infection in its early stages and the developement of resistance. There are also few comparative studies of drugs within the increasing number of antifungal agents which would Provide a reliable basis for choice.
